{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:46:38Z","timestamp":1789631198307,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr&x00E5;d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40264-018-0650-6","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T05:42:38Z","timestamp":1519882958000},"page":"685-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants"],"prefix":"10.1007","volume":"41","author":[{"given":"Maja","family":"Hellfritzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"issue":"11","key":"650_CR1","first-page":"1609","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2016;18(11):1609\u201378.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol."},{"issue":"353","key":"650_CR2","doi-asserted-by":"publisher","first-page":"i2607","DOI":"10.1136\/bmj.i2607","volume":"24","author":"SV Wang","year":"2016","unstructured":"Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016;24(353):i2607.","journal-title":"BMJ."},{"issue":"8","key":"650_CR3","first-page":"1215","volume":"17","author":"L Staerk","year":"2015","unstructured":"Staerk L, Gislason GH, Lip GYH, Fosb\u00f8l EL, Hansen ML, Lamberts M, et al. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2015;17(8):1215\u201322.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol."},{"issue":"5","key":"650_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","volume":"152","author":"NS Abraham","year":"2017","unstructured":"Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014\u201322.","journal-title":"Gastroenterology"},{"issue":"13","key":"650_CR5","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2017.13890","volume":"318","author":"CJD Wallis","year":"2017","unstructured":"Wallis CJD, Juvet T, Lee Y, Matta R, Herschorn S, Kodama R, et al. Association between use of antithrombotic medication and hematuria-related complications. JAMA. 2017;318(13):1260\u201371.","journal-title":"JAMA."},{"key":"650_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ebiom.2016.03.018","volume":"7","author":"A Potteg\u00e5rd","year":"2016","unstructured":"Potteg\u00e5rd A, Friis S, dePont Christensen R, Habel LA, Gagne JJ, Hallas J. Identification of associations between prescribed medications and cancer: a nationwide screening study. EBioMedicine. 2016;7:73\u20139.","journal-title":"EBioMedicine."},{"issue":"5","key":"650_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00001648-199609000-00005","volume":"7","author":"J Hallas","year":"1996","unstructured":"Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiol Camb Mass. 1996;7(5):478\u201384.","journal-title":"Epidemiol Camb Mass."},{"issue":"4","key":"650_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40264-015-0391-8","volume":"39","author":"IA Wahab","year":"2016","unstructured":"Wahab IA, Pratt NL, Ellett LK, Roughead EE. Sequence symmetry analysis as a signal detection tool for potential heart failure adverse events in an administrative claims database. Drug Saf. 2016;39(4):347\u201354.","journal-title":"Drug Saf."},{"key":"650_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1471-2288-14-66","volume":"14","author":"NL Pratt","year":"2014","unstructured":"Pratt NL, Ilom\u00e4ki J, Raymond C, Roughead EE. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol. 2014;14:66.","journal-title":"BMC Med Res Methodol."},{"issue":"5","key":"650_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","volume":"22","author":"IA Wahab","year":"2013","unstructured":"Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22(5):496\u2013502.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"650_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12186","volume":"275","author":"J Hallas","year":"2014","unstructured":"Hallas J, Potteg\u00e5rd A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275(6):581\u20139.","journal-title":"J Intern Med."},{"issue":"5462","key":"650_CR12","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","volume":"287","author":"L Frank","year":"2000","unstructured":"Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287(5462):2398\u20139.","journal-title":"Science."},{"issue":"3","key":"650_CR13","first-page":"798","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798.","journal-title":"Int J Epidemiol."},{"issue":"7 Suppl","key":"650_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30\u20133.","journal-title":"Scand J Public Health."},{"issue":"7 Suppl","key":"650_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22\u20135.","journal-title":"Scand J Public Health."},{"issue":"2","key":"650_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/pds.4350","volume":"27","author":"A Potteg\u00e5rd","year":"2018","unstructured":"Potteg\u00e5rd A, Grove EL, Hellfritzsch M. Use of direct oral anticoagulants in the first year after market entry of edoxaban: a Danish nationwide drug utilization study. Pharmacoepidemiol Drug Saf. 2018;27(2):174\u2013181.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"650_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bcpt.12664","volume":"120","author":"M Hellfritzsch","year":"2017","unstructured":"Hellfritzsch M, Husted SE, Grove EL, Rasmussen L, Poulsen BK, Johnsen SP, et al. Treatment changes among users of non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Basic Clin Pharmacol Toxicol. 2017;120(2):187\u201394.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"650_CR18","doi-asserted-by":"publisher","first-page":"31477","DOI":"10.1038\/srep31477","volume":"6","author":"L Staerk","year":"2016","unstructured":"Staerk L, Fosb\u00f8l EL, Gadsb\u00f8ll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011\u20132015 in Denmark. Sci Rep. 2016;6:31477.","journal-title":"Sci Rep."},{"issue":"7","key":"650_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC Lai","year":"2017","unstructured":"Lai EC, Pratt N, Hsieh C-Y, Lin S-J, Potteg\u00e5rd A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567\u201382.","journal-title":"Eur J Epidemiol."},{"issue":"5","key":"650_CR20","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/bcp.12696","volume":"80","author":"L Rasmussen","year":"2015","unstructured":"Rasmussen L, Hallas J, Madsen KG, Potteg\u00e5rd A. Cardiovascular drugs and erectile dysfunction\u2014a symmetry analysis. Br J Clin Pharmacol. 2015;80(5):1219\u201323.","journal-title":"Br J Clin Pharmacol."},{"issue":"8","key":"650_CR21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/pds.3635","volume":"23","author":"J Hallas","year":"2014","unstructured":"Hallas J, Christensen RD, St\u00fcrmer T, Potteg\u00e5rd A. Measures of \u201cexposure needed for one additional patient to be harmed\u201d in population-based case\u2013control studies. Pharmacoepidemiol Drug Saf. 2014;23(8):868\u201374.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"7168","key":"650_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309\u201312.","journal-title":"BMJ."},{"issue":"1","key":"650_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40264-013-0124-9","volume":"37","author":"IA Wahab","year":"2014","unstructured":"Wahab IA, Pratt NL, Kalisch LM, Roughead EE. Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf. 2014;37(1):53\u201364.","journal-title":"Drug Saf."},{"issue":"7 Suppl","key":"650_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1403494811399956","volume":"39","author":"LC Thygesen","year":"2011","unstructured":"Thygesen LC, Daasnes C, Thaulow I, Br\u00f8nnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39(7 Suppl):12\u20136.","journal-title":"Scand J Public Health."},{"issue":"9921","key":"650_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Lond Engl. 2014;383(9921):955\u201362.","journal-title":"Lancet Lond Engl."},{"issue":"12","key":"650_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","volume":"131","author":"AS Go","year":"1999","unstructured":"Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927\u201334.","journal-title":"Ann Intern Med."},{"issue":"12","key":"650_CR27","first-page":"899","volume":"38","author":"K Gadsb\u00f8ll","year":"2017","unstructured":"Gadsb\u00f8ll K, Staerk L, Fosb\u00f8l EL, Sindet-Pedersen C, Gundlund A, Lip GYH, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899\u2013906.","journal-title":"Eur Heart J."},{"issue":"12","key":"650_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med."},{"issue":"6","key":"650_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jjcc.2015.05.018","volume":"66","author":"T Morimoto","year":"2015","unstructured":"Morimoto T, Crawford B, Wada K, Ueda S. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol. 2015;66(6):466\u201374.","journal-title":"J Cardiol."},{"issue":"2","key":"650_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/joim.12628","volume":"282","author":"A Gundlund","year":"2017","unstructured":"Gundlund A, Staerk L, Fosb\u00f8l EL, Gadsb\u00f8ll K, Sindet-Pedersen C, Bonde AN, et al. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant? J Intern Med. 2017;282(2):164\u201374.","journal-title":"J Intern Med."},{"issue":"10","key":"650_CR31","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00228-017-2289-0","volume":"73","author":"J Komen","year":"2017","unstructured":"Komen J, Forslund T, Hjemdahl P, Wettermark B. Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. Eur J Clin Pharmacol. 2017;73(10):1315\u201322.","journal-title":"Eur J Clin Pharmacol."},{"issue":"21","key":"650_CR32","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689\u201396.","journal-title":"Circulation."},{"issue":"3","key":"650_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","volume":"95","author":"CS Landefeld","year":"1993","unstructured":"Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315\u201328.","journal-title":"Am J Med."},{"issue":"2","key":"650_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jjcc.2015.08.019","volume":"68","author":"M Nishino","year":"2016","unstructured":"Nishino M, Okamoto N, Tanaka A, Mori N, Hara M, Yano M, et al. Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban. J Cardiol. 2016;68(2):156\u201360.","journal-title":"J Cardiol."},{"issue":"4","key":"650_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12391","volume":"78","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, Gelbricht V, F\u00f6rster K, Ebertz F, R\u00f6llig D, Schreier T, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care\u2013results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014;78(4):908\u201317.","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"650_CR36","first-page":"1091","volume":"19","author":"M Hellfritzsch","year":"2017","unstructured":"Hellfritzsch M, Grove EL, Husted SE, Rasmussen L, Poulsen BK, Johnsen SP, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19(7):1091\u20135.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol."},{"issue":"2","key":"650_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11239-016-1452-2","volume":"43","author":"ZD Hale","year":"2017","unstructured":"Hale ZD, Kong X, Haymart B, Gu X, Kline-Rogers E, Almany S, et al. Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. J Thromb Thrombolysis. 2017;43(2):283\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"650_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med."},{"issue":"9","key":"650_CR39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806\u201317.","journal-title":"N Engl J Med."},{"issue":"12","key":"650_CR40","doi-asserted-by":"publisher","first-page":"e79109","DOI":"10.1371\/journal.pone.0079109","volume":"8","author":"RB Schnabel","year":"2013","unstructured":"Schnabel RB, Michal M, Wilde S, Wiltink J, Wild PS, Sinning CR, et al. Depression in atrial fibrillation in the general population. PLoS One. 2013;8(12):e79109.","journal-title":"PLoS One."},{"issue":"4","key":"650_CR41","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1378\/chest.07-0036","volume":"132","author":"G Thrall","year":"2007","unstructured":"Thrall G, Lip GYH, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest. 2007;132(4):1259\u201364.","journal-title":"Chest."},{"issue":"11","key":"650_CR42","first-page":"e609","volume":"21","author":"SK Schmitt","year":"2015","unstructured":"Schmitt SK, Turakhia MP, Phibbs CS, Moos RH, Berlowitz D, Heidenreich P, et al. Anticoagulation in atrial fibrillation: impact of mental illness. Am J Manag Care. 2015;21(11):e609\u201317.","journal-title":"Am J Manag Care."},{"issue":"9","key":"650_CR43","first-page":"617","volume":"17","author":"GA Walker","year":"2011","unstructured":"Walker GA, Heidenreich PA, Phibbs CS, Go AS, Chiu VY, Schmitt SK, et al. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011;17(9):617\u201324.","journal-title":"Am J Manag Care."},{"issue":"1","key":"650_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.12762","volume":"121","author":"M Hellfritzsch","year":"2017","unstructured":"Hellfritzsch M, Hyllested LMR, Meegaard L, Wiberg-Hansen A, Grove EL, Potteg\u00e5rd A. Switching, adverse effects and use of over-the-counter analgesics among users of oral anticoagulants: a pharmacy-based survey. Basic Clin Pharmacol Toxicol. 2017;121(1):37\u201343.","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"1","key":"650_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/joim.12360","volume":"278","author":"AM Shields","year":"2015","unstructured":"Shields AM, Lip GYH. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med. 2015;278(1):1\u201318.","journal-title":"J Intern Med."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0650-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T21:29:29Z","timestamp":1603920569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0650-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0650-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"1 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Maja Hellfritzsch declares speaker honoraria from Bristol-Myers Squibb and Pfizer. Lotte Rasmussen, Jesper Hallas, and Anton Potteg\u00e5rd declare participation in research projects funded by Boehringer-Ingelheim, with funds paid to the institution at which they were employed (no personal fees).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was funded by a Grant from the Danish Council for Independent Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}